[1]Perez EA, Mayo C, Div H, et al. Mierotubule inhibitors:Diferentiating tubulininhibiting agents based on mechanisms of aetion, clinie alactivity, and resistance[J]. Mol Cancer Ther, 2009, 8(8):2086-2095. [2]Banghman AD, Standish MM, Watkins JC. Diffusion of univalcntions across the lamella of swollen phospholipid[J]. J Mol Biol, 1965, 13(1):238-252. [3]Gregoriadis G, Leathwood PD, Ryman BE. Enzyme entrapment in liposomes[J]. FEBS Lett, 1971, 14(2):95-99. [4]Thomas FB, Paul C. Laut erbur1 nuclear magnet ic resonance techno logy f or medical studies[J]. Science, 1984, 226(4672):228. [5]Immordino ML, Brusa P, Arpicco S, et al. Prepar ation, characte rization, cytotoxicity and pha rma cokinetics of liposomes containing docet axel[J]. Control Release, 2003, 91(3):417. [6]程光, 陈文忠, 程昕伟, 等. 脂质体技术在抗肿瘤药物开发中的应用程[J]. 上海医药, 2010, 31(11):489-491. [7]Zhang JA, Anyarambhatla G, Ma L. Development and character ization of a novel Cremophor EL free liposome-based paclitaxel(LEP-ETU)formulation[J]. Eur J Pharm Biopharm, 2005, 59(1):177 -187. [8]Crosasso P, Cerut IM, Brusa P, et al. Preparation、characterization and properties of sterically stab-ilized paclitaxe-l containing liposomes[J]. J Control Release, 2000, 63(1-2):19-30. [9]张景京, 张志荣. 紫杉醇脂质体的制备和质量评价[J]. 华西药学杂志, 2001, 16(1):23-24. [10]阎家麒, 王悦, 王九一. 紫杉醇隐形脂质体的制备及在小鼠体内的组织分布[J]. 药学学报, 2000, 35(9):706-709. [11]净晓龙, 陈建明. 紫杉醇给药系统的研究进展[J]. 中国新药与临床杂志, 2011, 30(9):650-657. [12]Yoshizawa Y, Kono Y, Ogawara K, et al. PEG liposomalization of paclitaxel improved its in vivo disposition and antitumor effcacy[J]. Int J Pharm, 2011, 412(1-2):132-141. [13]Zhang JQ, Zhang ZR, Yang T, et al. Lyophilized paclitaxelm agn etoliposomes as a potentiald rug delivery system for breast car cinoma via paren teral adm in is tration:In vitro and in vivo studies[J]. Pharmaceutical Research, 2005, 22(4):573-582. [14]Bucke WE, Lectzke S, Diederichs JE, et al. Surface-modified amikacin-liposomes:organ distribution and interaction with plasma proteins[J]. Journal of Targeting, 1998, 5(2):99-108. [15]张晶晶, 方芸, 谈恒山, 等.中药脂质体的制备及应用[J]. 南京中医药大学学报, 2006, 22(3):202-204. [16]刘韬, 黄红兵, 林子超, 等. 多西紫杉醇脂质体的制备及稳定性考察[J]. 中国药房, 2007, 18(25):1958-1960. [17]杨涛, 金大德, 崔福德. 紫杉醇脂质体药物含量及包封率的测定[J]. 药物分析杂志, 2008, 28(2):231-234. [18]Zhang C, Newsome JT, Mewani R. Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonu-cleotides and siRNAs[J]. Methods Mol Biol. 2009, 4(8):65-83. [19]王 浩, 邓英杰. 紫杉醇冻干脂质体的制备及含量稳定性[J]. 沈阳药科大学学报, 2008, 25(8):609-614. [20]蒋天智, 刘少友. 新型长循环紫杉醇脂质体的制备及其细胞毒性[J]. 临床医学, 2007, 11(26):5113-5115. [21]刘素兰, 刘诗泆, 张海红. 脑靶向性紫杉醇脂质体的制备与靶向性研究[J]. 中国医院药学杂志, 2012, 32(24):1979-1983. |